Provided by Tiger Trade Technology Pte. Ltd.

BioAge Labs Inc.

21.14
+0.63003.07%
Volume:67.56K
Turnover:1.44M
Market Cap:882.65M
PE:-10.01
High:21.91
Open:20.53
Low:20.53
Close:20.51
52wk High:24.00
52wk Low:2.88
Shares:41.75M
Float Shares:28.58M
Volume Ratio:0.63
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1117
EPS(LYR):-6.6293
ROE:-25.64%
ROA:-17.46%
PB:3.18
PE(LYR):-3.19

Loading ...

BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

GlobeNewswire
·
Feb 20

BioAge Labs Raised to Buy From Hold by Jefferies

Dow Jones
·
Feb 18

Bioage Labs Inc : Jefferies Raises to Buy From Hold; Raises Target Price to $62 From $9

THOMSON REUTERS
·
Feb 18

BioAge Labs upgraded to Buy from Hold at Jefferies

TIPRANKS
·
Feb 18

Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Ansell (OtherANSLF)

TIPRANKS
·
Feb 16

Morgan Stanley Boosts Price Target on BioAge Labs to $23 From $12, Keeps Equalweight Rating

MT Newswires Live
·
Feb 04

BioAge Labs Initiated at Overweight by Piper Sandler

Dow Jones
·
Jan 27

BioAge Labs initiated with an Overweight at Piper Sandler

TIPRANKS
·
Jan 27

BioAge Labs: De-Risked NLRP3 Program and 2026 Clinical Catalysts Underpin Overweight/Buy Rating

TIPRANKS
·
Jan 27

U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings

Reuters
·
Jan 27

Bioage Labs Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $73

THOMSON REUTERS
·
Jan 27

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel

Reuters
·
Jan 23

BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital

Reuters
·
Jan 22

BUZZ-BioAge Labs edges down after stock sale hiked to $115 mln

Reuters
·
Jan 22

BRIEF-Bioage Announces Pricing Of Upsized $115 Million Public Offering

Reuters
·
Jan 22

Bioage Announces Pricing of Upsized $115.0 Million Public Offering

THOMSON REUTERS
·
Jan 22

BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies

Reuters
·
Jan 21

BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous

Reuters
·
Jan 21

BioAge Labs: Early-Stage Promise for BGE-102 Balanced by Long Timelines and Clinical Risk, Justifying Hold Rating

TIPRANKS
·
Jan 21

BioAge Labs Proposes Public Offering Worth $75 Million

MT Newswires Live
·
Jan 21